Connection
Christina Aquilante to Cost-Benefit Analysis
This is a "connection" page, showing publications Christina Aquilante has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.068 |
|
|
|
-
Aquilante CL, Lobmeyer MT, Langaee TY, Johnson JA. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy. 2004 Jun; 24(6):720-6.
Score: 0.048
-
Kile DA, MaWhinney S, Aquilante CL, Rower JE, Castillo-Mancilla JR, Anderson PL. A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1227-34.
Score: 0.021